# A Study of SNP-ACTH (1-39) Gel in Patients With Primary Membranous Nephropathy

> **NCT05696613** · PHASE3 · UNKNOWN · sponsor: **Cerium Pharmaceuticals, Inc.** · enrollment: 148 (estimated)

## Conditions studied

- Primary Membranous Nephropathy

## Interventions

- **DRUG:** SNP-ACTH (1-39) Gel
- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT05696613
- **Lead sponsor:** Cerium Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-03-13
- **Primary completion:** 2025-03-01
- **Final completion:** 2026-03-01
- **Target enrollment:** 148 (ESTIMATED)
- **Last updated:** 2024-04-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05696613

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05696613, "A Study of SNP-ACTH (1-39) Gel in Patients With Primary Membranous Nephropathy". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05696613. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*